Product Description
Mechanisms of Action: Epump
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Bosnia | Brazil | Chile | China | Croatia | Cyprus | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Lebanon | Malaysia | Malta | New Zealand | Norway | Pakistan | Poland | Russia | Serbia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Biomarin
Company Location: NOVATO CA 94949
Company CEO: Jean-Jacques Bienaimé
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Muscle Weakness
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SeND Home | P2 |
Recruiting |
Muscle Weakness |
2025-06-30 |